HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Polyol pathway exacerbated ischemia/reperfusion-induced injury in steatotic liver.

AbstractBACKGROUND:
The polyol pathway, a bypass pathway of glucose metabolism initiated by aldose reductase (AR), has been shown to play an important role in mediating tissue ischemia/reperfusion (I/R) impairment recently. Here, we investigated how and why this pathway might affect the fatty liver following I/R.
METHODS:
Two opposite models were created: mice with high-fat-diet-induced liver steatosis were treated with aldose reductase inhibition (ARI) and subsequent I/R; and AR-overexpressing L02 hepatocytes were sequentially subjected to steatosis and hypoxia/reoxygenation. We next investigated (a) the hepatic injuries, including liver function, histology, and hepatocytes apoptosis/necrosis; (b) the NAD(P)(H) contents, redox status, and mitochondrial function; and (c) the flux through the caspase-dependent apoptosis pathway.
RESULTS:
AR-inhibition in vivo markedly attenuated the I/R-induced liver injuries, maintained the homeostasis of NAD(P)(H) contents and redox status, and suppressed the caspase-dependent apoptosis pathway. Correspondingly, AR overexpression in vitro presented the opposite effects.
CONCLUSION:
The flux through the polyol pathway may render steatotic liver greater vulnerability to I/R. Interventions targeting this pathway might provide a novel adjunctive approach to protect fatty liver from ischemia.
AuthorsChanghe Zhang, Changjun Huang, Yuan Tian, Xiangcheng Li
JournalOxidative medicine and cellular longevity (Oxid Med Cell Longev) Vol. 2014 Pg. 963629 ( 2014) ISSN: 1942-0994 [Electronic] United States
PMID24967007 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • Polymers
  • polyol
  • Malondialdehyde
  • NADP
  • Aldehyde Reductase
  • Caspase 3
Topics
  • Aldehyde Reductase (antagonists & inhibitors, metabolism)
  • Animals
  • Apoptosis (drug effects)
  • Caspase 3 (metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Fatty Liver (enzymology, etiology, pathology)
  • Hepatocytes (drug effects, pathology)
  • Intracellular Space (drug effects, metabolism)
  • Liver (drug effects, enzymology, pathology)
  • Male
  • Malondialdehyde (metabolism)
  • Membrane Potential, Mitochondrial (drug effects)
  • Metabolic Networks and Pathways (drug effects)
  • Mice, Inbred C57BL
  • NADP (metabolism)
  • Oxidation-Reduction (drug effects)
  • Polymers (metabolism)
  • Reperfusion Injury (complications, enzymology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: